Ecnoglutide
What it is
Ecnoglutide (also identified as XW003) is a long-acting, cyclic adenosine monophosphate (cAMP) signalling-biased glucagon-like peptide-1 (GLP-1) receptor agonist developed by Sciwind Biosciences. It is a fatty-acid-conjugated (lipidated) peptide analogue of the incretin hormone GLP-1, built from natural amino acids and designed for once-weekly administration.
Research context and categorization
Ecnoglutide is grouped under the metabolic and weight regulation category, alongside other GLP-1 receptor agonists. In published clinical research it has been investigated for glycemic control in adults with type 2 diabetes and for body-weight reduction in adults with overweight or obesity. It has also been discussed in relation to non-alcoholic fatty liver disease and broader cardiometabolic endpoints.
These uses remain investigational in the United States. Ecnoglutide is not FDA-approved, and the research uses described here are being studied rather than confirmed or established. Reported trial findings, such as changes in HbA1c or percentage body-weight change, come from controlled study settings and should not be read as guaranteed benefits for any general use. Anyone reviewing the compound should treat it as an experimental reference material and not as a finished, approved product in the U.S. market.
Status
- Regulatory status: Research-only / not FDA-approved. Ecnoglutide is investigational in the United States. Ecnoglutide injection has reportedly received marketing approval from China's National Medical Products Administration (NMPA) for chronic weight management, but that is a foreign-market approval and does not apply to the U.S. or predict FDA action.
- Sport status: Not specifically listed on the WADA Prohibited List. GLP-1 receptor agonists as a class, such as semaglutide, are not currently prohibited and have been placed on WADA's Monitoring Program, which tracks use patterns without imposing sanctions while the class is under ongoing review. Ecnoglutide itself is not named on the Prohibited List, though the class status can change in future annual revisions.
Reconstitution notes (general)
Concentration equals the milligrams of compound in the vial divided by the millilitres of bacteriostatic water added. For example, a 5 mg vial reconstituted with 2 mL of bacteriostatic water yields 2.5 mg/mL. Adjust the water volume to reach whatever working concentration a protocol calls for, and use the calculator at /pages/tools to check the math before drawing anything up.
Dilution and handling notes (compound-specific)
The clinical product ships as a prepared "ecnoglutide injection," but research-grade material is typically supplied as a lyophilized (freeze-dried) powder that is reconstituted with bacteriostatic water before use. Published reconstitution data specific to ecnoglutide is limited, so handling generally follows the behavior of the lipidated GLP-1 analogue class it belongs to.
Working concentrations for GLP-1 analogue research vials commonly land in the low single-digit mg/mL range, often around 2.5 to 5 mg/mL, chosen so a full vial reconstitutes into a manageable volume and stays comfortably within its dissolved range. As a family, these peptides usually enter solution within roughly one to five minutes and produce a clear, colorless liquid when the water is added slowly down the vial wall rather than squirted directly onto the powder.
The compound-specific quirk worth noting is that ecnoglutide is a fatty-acid-conjugated peptide. Lipidated peptides of this type are more prone than simple peptides to aggregate, cloud, or gel at high concentration or when solution pH drifts, and they can foam readily if agitated. The practical takeaways: keep the concentration moderate rather than pushing the vial to a very high mg/mL, add the bacteriostatic water gently down the wall, and swirl rather than shake to limit foaming and protect the peptide structure. If the material does not fully clear, a few extra minutes of gentle swirling at room temperature usually resolves it; a solution that stays cloudy, gelled, or shows particles after that should not be used. Do not freeze the reconstituted solution, since freeze-thaw cycling can degrade peptide integrity.
Handling and storage
Refrigerate the reconstituted vial at 2 to 8 degrees Celsius and keep it out of direct light. Wipe the rubber stopper with an alcohol swab before each access. Label the vial with the mix date so the age of the solution is always clear, and observe the general, roughly 4-week refrigerated window for a reconstituted peptide of this type. Discard the vial if the contents turn cloudy or discolored, or if floaters or particulates appear.
Related reading
Tools and supplies
- Reconstitution & blend calculators
- Bacteriostatic Water 30 ml
- Gansulin Metal Reusable Pen
- 3 ml Glass Cartridges (10-pack)
- Complete Starter Kit
For laboratory and research reference only. Educational content, not medical, dosing, injection, or therapeutic guidance, and not intended for human or animal use. Any research uses described are investigational and not confirmed or approved benefits. Confirm anything involving health with a licensed professional. References linked above.